+++ US vs. China: Das könnten die Gewinner aus dem Handelskonflikt werden! Jetzt zum Webinar am 21.10. anmelden! +++ -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
21.07.2019 19:53:00

Amarin: Is a Buyout Really Off the Table?

Amarin (NASDAQ: AMRN) drew the ire of its shareholders last week by rolling out a breathtaking $460 million capital raise. The drugmaker's shares, in fact, fell by a noteworthy 17.4% last week in large part because of the sheer size of this public offering. This massive public offering caught shareholders flat-footed for two reasons. First up, the biopharma recently announced that sales of its prescription omega-3 treatment, Vascepa, have been going strong ever since the drug showed a 25% relative risk reduction in terms of serious cardiovascular events in the outcomes trial known as Reduce-It.Image Source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"